Clinical Trial Update: PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating toripalimab in combination with chemoradiotherapy for locally advanced colorectal cancer with dMMR/MSI-H status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Toripalimab (Toripalimab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: DMMR Colorectal Cancer, MSI-H Colorectal Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING